Quantitative elasticity measurements reveal intratumoral changes in response to antiangiogenic therapy - Preliminary results

Kenneth Hoyt, Jason M. Warram

Research output: Chapter in Book/Report/Conference proceedingConference contribution

1 Citation (Scopus)

Abstract

Vascular endothelial growth factor (VEGF) driven tumor neovasculature is known to be hyperpermeable, which in turn raises tumor interstitial fluid pressure and compromises delivery of chemotherapeutic agents. Antiangiogenic therapies inhibit the VEGF signaling pathway leading to increased intratumoral necrosis. The objective of this study was to measure changes in both tumor interstitial pressure and elasticity in response to antiangiogenic therapy. Forty nude athymic mice were implanted with adenocarcinoma cells in the mammary fat pad (20 controls and 20 in therapy group). The therapy mice group was administered bevacizumab three weeks thereafter. Ultrasound imaging (4 mice per group) was performed at days 0.1, 1, 3, and 6 with a Siemens Acuson S2000 system equipped with a 4V1 transducer. Repeated intratumoral elasticity measurements were acquired using the Virtual Touch feature. Subsequently, intratumoral pressure was measured using a needle-based device prior to mouse euthanasia. On average, control tumors grew larger (+7.2%) than bevacizumab-treated tumors (-29.2%). Quantitative elasticity measurements revealed that tumors treated with bevacizumab became much stiffer compared to controls. Matched intratumoral pressure measurements showed a precipitous decrease and peak at day 1 in the therapy group that trended towards zero change thereafter. Alternatively, control tumors exhibited only a slight increase in intratumoral pressure between days 1 and 6 matching the pattern observed in elasticity measurements from this same group. No correlation was found between matched tumor volume and elasticity measurements suggesting that tumor size did not impact elasticity measurements. Overall, this study indicates that quantitative elasticity measurements may be an adjunct indicator for assessing breast cancer response or no response to antiangiogenic therapy.

Original languageEnglish (US)
Title of host publication2009 IEEE International Ultrasonics Symposium and Short Courses, IUS 2009
DOIs
StatePublished - Dec 1 2009
Event2009 IEEE International Ultrasonics Symposium, IUS 2009 - Rome, Italy
Duration: Sep 20 2009Sep 23 2009

Other

Other2009 IEEE International Ultrasonics Symposium, IUS 2009
CountryItaly
CityRome
Period9/20/099/23/09

Fingerprint

therapy
tumors
elastic properties
mice
interstitials
fluid pressure
touch
necrosis
fats
pressure measurement
needles
breast
delivery
transducers
drugs
cancer
cells

Keywords

  • Antiangiogenic therapy
  • Bevacizumab
  • Breast cancer
  • Tissue elasticity
  • Ultrasound

ASJC Scopus subject areas

  • Acoustics and Ultrasonics

Cite this

Quantitative elasticity measurements reveal intratumoral changes in response to antiangiogenic therapy - Preliminary results. / Hoyt, Kenneth; Warram, Jason M.

2009 IEEE International Ultrasonics Symposium and Short Courses, IUS 2009. 2009. 5441503.

Research output: Chapter in Book/Report/Conference proceedingConference contribution

Hoyt, K & Warram, JM 2009, Quantitative elasticity measurements reveal intratumoral changes in response to antiangiogenic therapy - Preliminary results. in 2009 IEEE International Ultrasonics Symposium and Short Courses, IUS 2009., 5441503, 2009 IEEE International Ultrasonics Symposium, IUS 2009, Rome, Italy, 9/20/09. https://doi.org/10.1109/ULTSYM.2009.5441503
Hoyt, Kenneth ; Warram, Jason M. / Quantitative elasticity measurements reveal intratumoral changes in response to antiangiogenic therapy - Preliminary results. 2009 IEEE International Ultrasonics Symposium and Short Courses, IUS 2009. 2009.
@inproceedings{0ec3a90aec6d44938b58d6b1b885bae0,
title = "Quantitative elasticity measurements reveal intratumoral changes in response to antiangiogenic therapy - Preliminary results",
abstract = "Vascular endothelial growth factor (VEGF) driven tumor neovasculature is known to be hyperpermeable, which in turn raises tumor interstitial fluid pressure and compromises delivery of chemotherapeutic agents. Antiangiogenic therapies inhibit the VEGF signaling pathway leading to increased intratumoral necrosis. The objective of this study was to measure changes in both tumor interstitial pressure and elasticity in response to antiangiogenic therapy. Forty nude athymic mice were implanted with adenocarcinoma cells in the mammary fat pad (20 controls and 20 in therapy group). The therapy mice group was administered bevacizumab three weeks thereafter. Ultrasound imaging (4 mice per group) was performed at days 0.1, 1, 3, and 6 with a Siemens Acuson S2000 system equipped with a 4V1 transducer. Repeated intratumoral elasticity measurements were acquired using the Virtual Touch feature. Subsequently, intratumoral pressure was measured using a needle-based device prior to mouse euthanasia. On average, control tumors grew larger (+7.2{\%}) than bevacizumab-treated tumors (-29.2{\%}). Quantitative elasticity measurements revealed that tumors treated with bevacizumab became much stiffer compared to controls. Matched intratumoral pressure measurements showed a precipitous decrease and peak at day 1 in the therapy group that trended towards zero change thereafter. Alternatively, control tumors exhibited only a slight increase in intratumoral pressure between days 1 and 6 matching the pattern observed in elasticity measurements from this same group. No correlation was found between matched tumor volume and elasticity measurements suggesting that tumor size did not impact elasticity measurements. Overall, this study indicates that quantitative elasticity measurements may be an adjunct indicator for assessing breast cancer response or no response to antiangiogenic therapy.",
keywords = "Antiangiogenic therapy, Bevacizumab, Breast cancer, Tissue elasticity, Ultrasound",
author = "Kenneth Hoyt and Warram, {Jason M.}",
year = "2009",
month = "12",
day = "1",
doi = "10.1109/ULTSYM.2009.5441503",
language = "English (US)",
isbn = "9781424443895",
booktitle = "2009 IEEE International Ultrasonics Symposium and Short Courses, IUS 2009",

}

TY - GEN

T1 - Quantitative elasticity measurements reveal intratumoral changes in response to antiangiogenic therapy - Preliminary results

AU - Hoyt, Kenneth

AU - Warram, Jason M.

PY - 2009/12/1

Y1 - 2009/12/1

N2 - Vascular endothelial growth factor (VEGF) driven tumor neovasculature is known to be hyperpermeable, which in turn raises tumor interstitial fluid pressure and compromises delivery of chemotherapeutic agents. Antiangiogenic therapies inhibit the VEGF signaling pathway leading to increased intratumoral necrosis. The objective of this study was to measure changes in both tumor interstitial pressure and elasticity in response to antiangiogenic therapy. Forty nude athymic mice were implanted with adenocarcinoma cells in the mammary fat pad (20 controls and 20 in therapy group). The therapy mice group was administered bevacizumab three weeks thereafter. Ultrasound imaging (4 mice per group) was performed at days 0.1, 1, 3, and 6 with a Siemens Acuson S2000 system equipped with a 4V1 transducer. Repeated intratumoral elasticity measurements were acquired using the Virtual Touch feature. Subsequently, intratumoral pressure was measured using a needle-based device prior to mouse euthanasia. On average, control tumors grew larger (+7.2%) than bevacizumab-treated tumors (-29.2%). Quantitative elasticity measurements revealed that tumors treated with bevacizumab became much stiffer compared to controls. Matched intratumoral pressure measurements showed a precipitous decrease and peak at day 1 in the therapy group that trended towards zero change thereafter. Alternatively, control tumors exhibited only a slight increase in intratumoral pressure between days 1 and 6 matching the pattern observed in elasticity measurements from this same group. No correlation was found between matched tumor volume and elasticity measurements suggesting that tumor size did not impact elasticity measurements. Overall, this study indicates that quantitative elasticity measurements may be an adjunct indicator for assessing breast cancer response or no response to antiangiogenic therapy.

AB - Vascular endothelial growth factor (VEGF) driven tumor neovasculature is known to be hyperpermeable, which in turn raises tumor interstitial fluid pressure and compromises delivery of chemotherapeutic agents. Antiangiogenic therapies inhibit the VEGF signaling pathway leading to increased intratumoral necrosis. The objective of this study was to measure changes in both tumor interstitial pressure and elasticity in response to antiangiogenic therapy. Forty nude athymic mice were implanted with adenocarcinoma cells in the mammary fat pad (20 controls and 20 in therapy group). The therapy mice group was administered bevacizumab three weeks thereafter. Ultrasound imaging (4 mice per group) was performed at days 0.1, 1, 3, and 6 with a Siemens Acuson S2000 system equipped with a 4V1 transducer. Repeated intratumoral elasticity measurements were acquired using the Virtual Touch feature. Subsequently, intratumoral pressure was measured using a needle-based device prior to mouse euthanasia. On average, control tumors grew larger (+7.2%) than bevacizumab-treated tumors (-29.2%). Quantitative elasticity measurements revealed that tumors treated with bevacizumab became much stiffer compared to controls. Matched intratumoral pressure measurements showed a precipitous decrease and peak at day 1 in the therapy group that trended towards zero change thereafter. Alternatively, control tumors exhibited only a slight increase in intratumoral pressure between days 1 and 6 matching the pattern observed in elasticity measurements from this same group. No correlation was found between matched tumor volume and elasticity measurements suggesting that tumor size did not impact elasticity measurements. Overall, this study indicates that quantitative elasticity measurements may be an adjunct indicator for assessing breast cancer response or no response to antiangiogenic therapy.

KW - Antiangiogenic therapy

KW - Bevacizumab

KW - Breast cancer

KW - Tissue elasticity

KW - Ultrasound

UR - http://www.scopus.com/inward/record.url?scp=77952852065&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77952852065&partnerID=8YFLogxK

U2 - 10.1109/ULTSYM.2009.5441503

DO - 10.1109/ULTSYM.2009.5441503

M3 - Conference contribution

SN - 9781424443895

BT - 2009 IEEE International Ultrasonics Symposium and Short Courses, IUS 2009

ER -